Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

Abstract outlines data showing enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer patients with NECTIN4 gene amplification Company to announce topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer and topline monotherapy data for zelenectide pevedotin in non-small cell lung cancer Conference call and webcast scheduled for Friday, Dec. 13, at 7 a.m. CT to review all data CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Nov. 25, 2024-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer (TNBC) patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Cancer Symposium (SABCS) taking place December 10-13 in San Antonio, Texas. In conjunction with the SABCS poster presentation, Bicycle Therapeutics will also announce topline combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer, and topline monotherapy data for zelenectide pevedotin in non-small cell lung cancer patients with NECTIN4 gene amplification. The company will host a conference call and webcast for analysts and investors to review the updated data for zelenectide pevedotin. Poster Presentation: Title: Enhanced anti-tumor activity of zelenectide pevedotin in triple negative breast cancer (TNBC) patients (pts) with NECTIN4 gene amplification (amp) Session Number: 4 Date and Time: Thursday, Dec. 12, at 5:30-7 p.m. CT Presentation Number: P4-10-21 Lead Author: Niklas Klümper, M.D., University Hospital Bonn Conference Call and Webcast Information Bicycle Therapeutics will host a conference call and webcast on Friday, Dec. 13, at 7 a.m. CT to review the data updates for zelenectide pevedotin. To access the call, please dial +1-833-816-1408 (U.S.) or +1-412-317-0501 (international) and ask to join the Bicycle Therapeutics call. A live webcast and replay of the conference call will be available in the Investor section of the company’s website, www.bicycletherapeutics.com. About Bicycle Therapeutics Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20241125297563/en/ Investors: Stephanie Yao SVP, Investor Relations and Corporate Communications [email protected] 857-523-8544 Matthew DeYoung Argot Partners [email protected] 212-600-1902 Media: Jim O’Connell Weber Shandwick [email protected] 312-988-2343 Source: Bicycle Therapeutics plc Press Releases Close IR Nav Overview →Stock Information →SEC Filings →Annual General Meeting →UK Annual Reports →Governance + Leadership →Presentation + Events →Analyst Coverage →Press Releases →Investor Resources → IR Nav Overview Stock Information SEC Filings Annual General Meeting UK Annual Reports Governance + Leadership Presentation + Events Analyst Coverage Press Releases Investor Resources United Kingdom Blocks A & B Portway Building Granta Park Great Abington Cambridge CB21 6GP View Google Map United States 4 Hartwell Place Lexington, MA 02421 View Google Map General Enquiries [email protected] Follow LinkedIn Twitter Privacy © Bicycle Therapeutics 2026 Designed by Greenspace Sign up Search Close Search Search → Hello We use cookies and other technologies to optimise your experience and analyse our traffic. Please confirm you are happy to accept. You can change your preferences in Cookie Settings. Find out more Accept var s_CCSWebHostingAccount = "trcgbicycle"; {"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/10441","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb78741\/themes\/site\/nir_pid3307"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyNkdFuQyEIhl-oOTbpxR6HoLLWHYUToNv69rW6pO2yZYsXCn7y8yMXBWSsFy_JAj9GC2aJBBXPnE47_hPcVPLAIhoNoiRhe065SI2oI5lWysVFIaP3FStZuB-XVxV24lmzoa7kg4RYJa1hyJuDohc-doVe8ITq_8INhsgvbCNkUErSWtfvD4Qfa5-rl9Zbx_AcjtsNj9Pp7bDgG34C5gypohlgJXX7gUvDqoNdOHUrzDRHtJV8OOxfgryTasmz4Q-KVpyApU-f5md8yy1f-866Z2rhNv8rJ2XCOg","theme":"nir_pid3307","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"364a63fdd1ba8bf28808b7d4a735dfbd500f3bdd6295cc883846cac82cce7d97"}}

The release as fetched from its publisher. bicycletherapeutics.com ↗